The comparable efficacy and favorable safety profile vs. daily therapy strengthens TransCon hGH’s differentiation as a once-weekly treatment, potentially driving adoption in Turner syndrome and supporting future label expansion. Traders should monitor progress in the Phase 3 HighLiGHts trial as a key catalyst.
Price Chart
Executive Summary
Ascendis Pharma announced positive Week 52 results from its Phase 2 New InsiGHTS trial, showing that once-weekly TransCon hGH achieved annualized height velocity (9.05 cm/year) comparable to daily somatropin (9.04 cm/year) in children with Turner syndrome, with a similar safety profile and no cases of slipped capital femoral epiphysis. The data support ongoing Phase 3 HighLiGHts trial efforts for potential label expansion into growth hormone sufficiency indications.
Key Facts
- TransCon hGH demonstrated annualized height velocity of 9.05 cm/year (LS mean) at Week 52, vs. 9.04 cm/year for daily somatropin
- Trial included 49 prepubertal children with Turner syndrome aged 1–10 years
- No occurrences of slipped capital femoral epiphysis (SCFE) in TransCon hGH group
- Adverse events were mild to moderate; none led to discontinuation
- Mean weekly dose: 0.22 mg/kg for TransCon hGH vs. 0.29 mg/kg for daily somatropin
- Safety follow-up extended up to 143 weeks with comparable tolerability
- Phase 3 HighLiGHts basket trial is now underway to support label expansion
Financial Impact
Potential for expanded market share in pediatric growth disorders; supports premium pricing and reimbursement positioning for once-weekly TransCon hGH
Risk Factors
- Regulatory approval not guaranteed despite positive Phase 2 data
- Phase 3 trial may not replicate efficacy or safety findings
- Competition from existing and emerging growth hormone therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257185 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access